CTA is pleased to support the recent publication by Hitchen N, Shahnam A, Manoharan S et al, reviewing trends in Phase 1 oncology clinical trials across Australia. This paper [...]
With both artificial intelligence and cybersecurity now squarely in the public eye, Dr. Dishan Herath brings a new perspective as the newest member of the Cancer Trials Australia Board. [...]
CTA’s June 2024 team development day was a Spanish Cooking class. Staff were split into four groups, working together to prepare the first part of the menu, making delicious [...]
I am pleased to share with you our 2023 Annual Report, released at our recent Annual General Meeting on 22 May, 2024. Please click here to access the report. The 2023 [...]
In mid-November, CTA was pleased to offer a Stress and Resilience Workshop for all staff, delivered by Bailey Opie, a Performance Psychologist at The Mind Room. We were extremely [...]
In late November CTA was pleased to host our second Developmental Therapeutics Update Dinner meeting for 2023, presented with the generous support of the Series sponsors, namely Amgen, AstraZeneca, [...]
In late October CTA was pleased to host our Annual Research Managers’ Day, a site driven, in-person forum that continues to grow in popularity each year. In 2023 we [...]
I am pleased to share with you our 2022 Annual Report, released at our recent Annual General Meeting on 24 May, 2023. This Annual Report also takes the opportunity [...]
I am pleased to share with you the 2021 Cancer Trials Australia Annual Report, released at our recent Annual General Meeting on 18 May, 2022. Please click here to access [...]
Welcoming Associate Professor Jayesh Desai as the Incoming Chairperson of the Cancer Trials Australia Board of Directors As his six-year tenure draws to a conclusion, outgoing Cancer Trials [...]
I am pleased to share with you the 2020 Cancer Trials Australia Annual Report, released at our recent Annual General Meeting.Please click here to access the reportAs the report describes, despite [...]
In a major milestone for Australian cancer patients, the not-for-profit, member-based organisation, Cancer Trials Australia (CTA), has recently marked the recruitment of the 10,000th oncology patient to clinical trials [...]
Isolation is tough, especially when your workplace is a great place to be - the lack of incidental chatter and the enjoyment that comes from interacting with our workmates [...]
I am pleased to share with you the 2019 Cancer Trials Australia Annual Report. Download the 2019 Annual Report Here. The 2019 calendar year saw continued growth in both [...]
Cancer Trials Australia (CTA) is pleased to announce that a Phase 1 Oncology Clinical Trials Fellowship Program will be piloted in Victoria throughout 2020 and 2021 in partnership with [...]
Cancer Trials Australia’s CEO, Dr. Kurt Lackovic, was a panelist at the 12th annual ‘China Trials – Clinical Development Leaders’ summit’ in Shanghai this week. Other panelists included Jayden [...]
Cancer Trials Australia (CTA) is pleased to announce a new project, to be delivered with the Victorian Comprehensive Cancer Centre (VCCC), providing Victorian sites with an exciting opportunity to [...]
Working closely with Marian Lieschke, Heike Raunow and Kylie Shackleton, CTA’s 2019 Research Manager’s Day was held on 17 October. 18 participants joined this highly productive forum from across [...]
By 2021, the global market for clinical trials is anticipated to grow to $60Bn, a 75% increase over 2015. The largest contributor to this huge growth is the Asia-Pacific region.Cancer [...]
CTA has experienced significant growth over recent years, which has accelerated throughout 2019. Dedicating time to team development activities not only helps to integrate new staff into the wider [...]
I am pleased to share with you the 2018 Cancer Trials Australia Annual Report. Download the 2018 Annual Report Here. The 2018 calendar year saw growth in both CTA [...]
Invest Victoria recently profiled the strength of interactions between Cancer Trials Australia and BeiGene, a rapidly growing Chinese biopharmaceutical company, with over 1,700 staff across four continents and more than [...]
CTA has executed an MOU with ShareRoot Limited (ASX: SRO) to explore the application of ShareRoot’s MediaConsent platform as a tool to improve the dynamics of clinical trial recruitment, patient [...]
CTA announces partnership in delivering coordinated Electronic Document Management for Victorian study sites Cancer Trials Australia (CTA) is pleased to announce a new project funded by the Victorian Comprehensive [...]
Due to an improved partnership between South West Healthcare (SWH) and CTA, cancer patients will have greater access to potentially life-saving therapies they may not have otherwise had access to. SWH medical oncologist Ian [...]
